SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX

SG Americas Securities LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 51.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 19,997 shares of the company’s stock after selling 21,249 shares during the quarter. SG Americas Securities LLC’s holdings in Protagonist Therapeutics were worth $1,747,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Voya Investment Management LLC increased its position in shares of Protagonist Therapeutics by 8.9% during the third quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after acquiring an additional 25,065 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock valued at $411,601,000 after purchasing an additional 24,000 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Protagonist Therapeutics by 123.1% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 90,317 shares of the company’s stock worth $6,000,000 after buying an additional 49,833 shares during the period. Mangrove Partners IM LLC boosted its holdings in shares of Protagonist Therapeutics by 21.0% in the third quarter. Mangrove Partners IM LLC now owns 478,413 shares of the company’s stock worth $31,781,000 after acquiring an additional 83,030 shares during the period. Finally, Natixis purchased a new position in Protagonist Therapeutics during the 2nd quarter valued at about $2,324,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insiders Place Their Bets

In other Protagonist Therapeutics news, Director Lewis T. Williams sold 18,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $644,936.50. This represents a 69.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 20,000 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $654,796. This trade represents a 71.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 321,632 shares of company stock worth $29,087,253 in the last quarter. Insiders own 4.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PTGX shares. Leerink Partners increased their price target on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Weiss Ratings downgraded shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, February 17th. The Goldman Sachs Group increased their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a research report on Tuesday, March 3rd. Citigroup boosted their target price on Protagonist Therapeutics from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Finally, Barclays raised their target price on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $107.31.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $103.78 on Monday. The firm has a market cap of $6.62 billion, a P/E ratio of -50.62 and a beta of 2.12. Protagonist Therapeutics, Inc. has a fifty-two week low of $39.60 and a fifty-two week high of $107.84. The firm has a 50-day simple moving average of $90.97 and a two-hundred day simple moving average of $84.24.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). The firm had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%. On average, equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.